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SObjective: We used a population-based data set to assess the association between the extent of pulmonary re-
section for bronchoalveolar carcinoma and survival. The reports thus far have been limited to small, institutional
series.
Methods: Using the Surveillance, Epidemiology, and End Results database (1988–2007), we identified patients
with bronchoalveolar carcinoma who had undergone wedge resection, segmentectomy, or lobectomy. The bron-
choalveolar carcinoma histologic findings were mucinous, nonmucinous, mixed, not otherwise specified, and
alveolar carcinoma. To adjust for potential confounders, we used a Cox proportional hazards regression model.
Results: A total of 6810 patients met the inclusion criteria. Compared with the sublobar resections (wedge re-
sections and segmentectomies), lobectomy conferred superior 5-year overall (59.5% vs 43.9%) and cancer-
specific (67.1% vs 53.1%) survival (P<.0001). After adjusting for potential confounding patient and tumor
characteristics, we found that patients who underwent an anatomic resection had significantly better overall
(segmentectomy: hazard ratio, 0.59; 95% confidence interval, 0.43–0.81; lobectomy: hazard ratio, 0.50; 95%
confidence interval, 0.44–0.57) and cancer-specific (segmentectomy: hazard ratio, 0.51; 95% confidence
interval, 0.34–0.75; lobectomy: hazard ratio, 0.46; 95% confidence interval, 0.40–0.53) survival compared
with patients who underwent wedge resection. Additionally, gender, race, tumor size, and degree of tumor
de-differentiation were negative prognostic factors. Our results were unchanged when we limited our analysis
to early-stage disease.
Conclusions: Using a population-based data set, we found that anatomic resections for bronchoalveolar carci-
noma conferred superior overall and cancer-specific survival rates compared with wedge resection. Bronchoal-
veolar carcinoma’s propensity for intraparenchymal spread might be the underlying biologic basis of our
observation of improved survival after anatomic resection. (J Thorac Cardiovasc Surg 2012;143:591-600)Earn CME credits at
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The Journal of Thoracic and CaIn the surgical treatment of non–small cell lung cancer
(NSCLC), there is an evolving interest and emphasis in
parenchymal-sparing operations for appropriately sized tu-
mors.1-3 Thus far, data on the association between the extent
of resection and survival have been limited to single-
institutional series,4-7 a randomized trial of all NSCLC
histologic findings,8 and analyses of administrative data
sets limited to patients with the most common NSCLC his-
tologic types (ie, adenocarcinoma and squamous cell
carcinoma).9
Interest in bronchoalveolar cell carcinoma (BAC) as
a separate histologic type or subclass of adenocarcinoma
is evolving.10-12 Historically, radiographic findings of
infiltrative or mass-like patterns could correlate with mucin-
ous or nonmucinous histologic findings.13 In the spring of
2011, the current understanding of BAC has brought into
the nomenclature the new terms of ‘‘adenocarcinoma in
situ,’’ ‘‘minimally invasive adenocarcinoma,’’ and ‘‘invasive
adenocarcinoma.’’14 How these new classifications will af-
fect treatment will be elucidated during the upcoming years.
Traditional teaching is that a lesion with BAC histologic
features undergoes wedge resection to free margins.rdiovascular Surgery c Volume 143, Number 3 591
Abbreviations and Acronyms
BAC ¼ bronchoalveolar cell carcinoma
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
SEER ¼ Surveillance, Epidemiology, and End
Results
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SSublobar resections have also been advocated.15,16 To date,
the published data on the association between the sublobar
resections for BAC and survival has been limited to small
series.17-19 To our knowledge, no studies have been
published that have used larger data sets to compare
survival after lobectomy versus sublobar resection
(anatomic segmentectomy and wedge resection) for BAC.
The analysis of these lesions is complicated by the
dominant cellular type, the presence of pure cellular
histologic features, and the extent of resection.
We hypothesized that a lobar resection would yield a su-
perior overall and cancer-specific survival rates for BAC
compared with a sublobar resection (segmentectomy and
wedge resection); and that an anatomic resection (lobec-
tomy or segmentectomy) would yield superior overall and
cancer-specific survival compared with nonanatomic resec-
tion (wedge resection). To evaluate these hypotheses using
population-based data, we queried the Surveillance, Epide-
miology, and End Results (SEER) database.
MATERIALS AND METHODS
The SEER database, founded in 1973 by the National Cancer Institute
(Bethesda, Md), is a data set that includes data from 17 cancer registries,
encompassing approximately 26% of the U.S. population. We used data
from the November 2009 submission, which provides data through Decem-
ber 31, 2007. We limited our analysis to data collected from January
1, 1988 (the year SEER began collecting American Joint Committee on Can-
cer staging data), through December 31, 2007. Because the SEER registries
did not differentiate the types of sublobar resections (ie, wedge resections
and segmentectomies) until 1998, our survival analysis comparing wedge
resection, segmentectomy, and lobectomy was limited to data obtained
from January 1, 1998 through December 31, 2007. Because of the negative
affect of Hurricane Katrina on data collection by the Louisiana SEER
registry, we excluded information obtained by that registry in 2005. We col-
lected information on patient factors (ie, age, race, and gender), tumor char-
acteristics (ie, size, grade, and histologic type), treatment factors (ie, extent
of resection and lymph node yield), and geographic treatment location
(determined by cancer registry in which the data were collected).
For our analysis, we included patients 18 years and older who under-
went either lobectomy or sublobar resection for BAC. The BAC histologic
subtypes were categorized as follows: BAC not otherwise specified, alve-
olar, nonmucinous, mucinous, and mixed type. To eliminate the potential
for confounding, mixed adenocarcinoma–BAC histologic types were
excluded.
Patients with more than 1 primary tumor were excluded. Those patients
with Stage IV disease were excluded. Because of the potential for con-
founding, we also excluded those patients who were unlikely to have re-
ceived aggressive cancer treatment (ie, patients with a hospice, nursing
home, autopsy, or death certificate as their only reporting source).592 The Journal of Thoracic and Cardiovascular SurgA previous study using SEER data found that survival after resection of
NSCLCwas optimized when 11 to 16 lymph nodes were examined.20 Con-
sequently, the lymph node counts were categorized as follows: 0, 1 to 10, 11
to 16, and 17 or more lymph nodes.
The data were analyzed with SAS, version 9.1 (SAS Institute, Cary,
NC). For all statistical testing, we used a 2-sided significance level of
.05. For between-group comparisons, we used a chi-square test for categor-
ical variables. The Kaplan-Meier method was used to compare the unad-
justed all-cause mortality and cancer-specific mortality rates between
sublobar resection and lobectomy. To adjust our survival analysis for poten-
tially confounding patient and tumor factors, we used a Cox proportional
hazards regression model. Log–log survival plots were generated after
the proportional hazards assumption was tested to assess for homogeneity
of the hazards ratio over time.RESULTS
Lobar Versus Sublobar (Segmentectomy and Wedge
Resection)
From our query of the SEER data set, we identified 6810
patients who met our inclusion criteria (Figure 1). Of these,
5532 patients underwent lobectomy and 1278 underwent
sublobar resection (Table 1). Of those with sublobar resec-
tions, 768 underwent wedge resection. From our Kaplan-
Meier analyses, we found that lobectomy was associated
with significantly better overall survival and cancer-
specific survival compared with sublobar resection
(Figure 2). When the sublobar resections were separated
into segmentectomy and wedge resection and analyzed us-
ing theKaplan-Meier method, we observed similarly, highly
significant, differences in overall and cancer-specific sur-
vival. The survival curves for the segmentectomy and lobec-
tomy patients were essentially indistinguishable.
When we adjusted our survival analysis to account for
potential confounders using a Cox proportional hazards re-
gression model, we found that lobectomy was an indepen-
dent predictor of improved all-cause and cancer-specific
mortality compared with sublobar resection (Table 2). We
also compared anatomic resections (lobectomy and seg-
mentectomy) and wedge resection. Both anatomic segmen-
tectomy and lobectomy were independently associated with
improved all-cause and cancer-specific mortality compared
with wedge resection. No significant difference was found
in survival between the patients who underwent lobectomy
and those who underwent anatomic segmentectomy
(Table 3).Patient Age
For the entire study population, the mean age was 67.3
10.3 years. For those who underwent wedge resection, the
mean age was 67.6  11 years. For those who underwent
segmentectomy, the mean age was 69.6  10.4 years. For
those who underwent lobectomy, the mean age was 67.2
 10.2 years. Most patients were elderly (Table 1). From
our multivariate analysis, increasing age was associated
with an increased risk of death (Tables 2 and 3).ery c March 2012
TABLE 1. Lobectomy versus segmentectomy versus wedge cohort
demographics
Variable Lobectomy Segmentectomy Wedge
P
value
Patients (n) 5532 152 768
Age (y) .003*
<40 0.7 1.3 1.4
40–49 5.0 3.3 5.3
50–59 16.3 11.8 14.5
60–69 32.3 23.7 29.6
70–79 35.7 42.8 37.3
>80 10.0 17.1 12
Race .037*
White 83.7 82.2 84.3
Black 6.6 9.2 8.63
Other 9.7 8.6 7.06
Gender .28
Male 37.7 40.1 35
Female 62.3 59.1 65
Tumor size (cm) <.0001*
<2 24.9 39.3 52.7
2–2.9 32.1 35.9 24.7
3–3.9 19.6 15.2 11.2
4–4.9 8.9 3.5 4.1
5–5.9 4.6 0.7 2.6
6–6.9 3 0.7 1.1
7 7 4.8 3.7
Lymph nodes
examined (n)
< .0001*
0 8.4 43 62.8
1–10 70.6 52.1 31.5
11–16 13.6 4.23 4
17 7.5 0.7 1.8
Histologic type (%) < .0001*
Not otherwise
specified
88.2 80.9 81.6
Alveolar carcinoma 1 2 0.3
Nonmucinous 4.4 11.2 7.7
Mucinous 5.5 5.3 9.5
Mixed type 0.9 0.7 0.9
Grade (%) .034*
Well differentiated 45.8 41.8 52.6
Moderately
differentiated
42.2 48.2 35.2
Poorly
differentiated
11.5 10 11.3
Undifferentiated 0.6 0 1
*Statistically significant.
FIGURE 1. Sample inclusion and exclusion selection criteria.BAC,Bron-
choalveolar cell carcinoma; SEER, Surveillance, Epidemiology, and End
Results.
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In the whole study population, more than 80% were
white, with the remainder black and other ethnicities
(Table 1). Black race was associated with a greater risk of
all-cause and cancer-specific mortality (Tables 2 and 3).
Gender
In both analyses, approximately two thirds of the patients
were women (Table 1). Men had significantly greater all-
cause and cancer-specific mortality rates in both the lobar
versus sublobar and anatomic versus nonanatomic resection
analyses (Tables 2 and 3).
Tumor Size
For those patients who underwent lobectomy, the greatest
proportion of tumor sizes was from 2 to 2.9 cm in diameter.
This was followed by less than 2 cm to 3 to 3.9 cm. For those
undergoing sublobar resection, the greatest proportion were
those with a size less than 2 cm (47.7%). In the sublobar re-
sections, increasing size became progressively less fre-
quent. For those patients who underwent segmentectomy
(Table 1), the proportion of tumors less than 2 cm in diam-
eter and those 2 to 2.9 cm in diameter was roughly the same
(39.3% and 35.9%). For the wedge resection cohort, most
(52.7%) were less than 2 cm in diameter and tumor 2 to 2.9
cm in diameter were found 24.7% of the time. In all 4 of the
Cox proportional hazards models, each incremental in-
crease in tumor size was associated with an increase in
the risk of mortality (all-cause and cancer-specific).
On Kaplan-Meier survival analysis, significant differ-
ences were found in survival when the tumors were grouped
by those less than or equal to 2 cm and those greater than 2
cm in diameter (data not shown). For overall and cancer-
specific survival, for tumors less than 2 cm in diameter,
the P value was< .0001. For tumors greater than 2 cm in
diameter, the P value for overall survival was< .0001 andThe Journal of Thoracic and Cafor cancer-specific survival was .0003. In the graphs of
the survival curves, the segmentectomy and lobectomy
curves overlapped. Those with wedge resections did worse.
On multivariate analysis of those tumors less than or
equal to 2 cm in diameter with the Cox proportional hazards
model (Table 4), segmentectomies and lobectomies resulted
in superior survival compared with wedge resection. No dif-
ference was found between segmentectomy and lobectomyrdiovascular Surgery c Volume 143, Number 3 593
FIGURE 2. (A) Overall survival and (B) cancer-specific survival for patients with bronchoalveolar cell carcinoma histologic features who underwent either
lobar or sublobar resection. (C) Overall survival and (D) cancer-specific survival for those patients who underwent anatomic resection (lobectomy or seg-
mentectomy) and nonanatomic resection (wedge resection). Survival denoted on y-axis, with time in months along x-axis. Below the graph, number at risk
for each is indicated.
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P ¼ .2891).
For those tumors greater than 2 cm in diameter (Table 4),
a lobectomy operation was superior to wedge resection. A
segmentectomy did not have significantly different survival
compared with wedge resection. No difference was found
between segmentectomy and lobectomy in terms of survival
(overall survival, P ¼ .6395; cancer-specific survival,
P ¼ .8606).
Lymph Nodes Examined
In lobar resections, 70.6% of patients had 1 to 10 lymph
nodes examined (Table 1). However, 43% of segmentecto-
mies and 62.8% of wedge resections had had no lymph no-
des evaluated. Only 4.8% of the sublobar resections had
more than 10 lymph nodes evaluated. In both lobar versus
sublobar and anatomic versus nonanatomic resection
models, each incremental increase in lymph node numbers
evaluated corresponded with an increasingly more favor-
able hazard ratio for both all-cause and cancer-specific mor-
tality (Tables 2 and 3).
Grade
Well-differentiated grade BAC was the most prevalent in
both lobar and sublobar cohorts. Between the sublobar594 The Journal of Thoracic and Cardiovascular Surggroups, those undergoing segmentectomy had a greater pro-
portion of moderately differentiated tumors compared with
those undergoing wedge resection, who had a greater pro-
portion of well-differentiated tumors (Table 1). In both
Cox proportional hazards models, greater degrees of de-
differentiation were associated with greater all-cause and
cancer-specific mortality (Tables 2 and 3).DISCUSSION
In 1995, the Lung Cancer Study Group reported the re-
sults of a prospective multi-institutional trial of limited re-
sections for early-stage (American Joint Committee on
Cancer Stage I or II NSCLC). The histologic subtypes eval-
uated in the that landmark analysis were simply classified as
nonsquamous and squamous.8 Since then, adenocarcinoma
(one of many ‘‘nonsquamous’’ histologic types) and its his-
tologic subtypes (eg, BAC) have become increasingly im-
portant. In particular, our evolving understanding of the
natural history and biologic behavior of BAC has brought
into question the generalizability of the Lung Cancer Study
Group findings for patients with BAC.10-12,21,22
Although it is a relatively rare subtype (approximately
4% of NSCLC histologic types),11,23,24 BAC has
a distinct natural history compared with other NSCLCery c March 2012
TABLE 3. Cox proportional hazards regression model for all-cause
and cancer-specific mortality for lobar versus segmentectomy versus
wedge resections
Variable
All-cause
mortality*
Cancer-specific
mortality*
Surgical approach
Wedge Reference Reference
Segmentectomy 0.58 (0.42–0.79) 0.49 (0.33–0.72)
Lobectomy 0.53 (0.47–0.61) 0.49 (0.42–0.56)
Age (y)
<40 Reference Reference
40–49 0.92 (0.56–1.51) 0.93 (0.55–1.57)
50–59 1.07 (0.67–1.7) 0.96 (0.58–1.57)
60–69 1.26 (0.8–1.99) 1.08 (0.66–1.75)
70–79 1.53 (0.97–2.42) 1.21 (0.74–1.96)
>80 2.19 (1.37–3.48) 1.50 (0.91–2.48)
Race
White Reference Reference
Black 1.26 (1.09–1.45) 1.32 (1.12–1.55)
Other 1.06 (0.91–1.23) 1.09 (0.92–1.57)
Gender
Female Reference Reference
Male 1.53 (1.42–1.66) 1.44 (1.31–1.57)
Tumor size (cm)
<2 Reference Reference
2–2.9 1.04 (0.93–1.16) 0.99 (0.87–1.13)
3–3.9 1.33 (1.18–1.5) 1.32 (1.15–1.52)
4–4.9 1.97 (1.71–2.27) 2.12 (1.8–2.5)
5–5.9 1.84 (1.54–2.21) 1.99 (1.61–2.46)
6–6.9 2.52 (2.03–3.13) 2.97 (2.33–3.77)
7 3.71 (3.21–4.29) 4.54 (3.87–5.33)
Lymph nodes examined
0 Reference Reference
1–10 0.85 (0.78–0.93) 0.84 (0.76–0.93)
11–16 0.73 (0.63–0.84) 0.71 (0.59–0.84)
17 0.66 (0.54–0.81) 0.68 (0.54–0.86)
Grade
Well differentiated Reference Reference
Moderately differentiated 1.44 (1.30–1.6) 1.45 (1.28–1.63)
Poorly differentiated 2.23 (1.96–2.55) 2.62 (2.26–3.05)
Undifferentiated 1.38 (1.24–1.53) 1.42 (1.26–1.61)
Data presented as hazard ratios and 95% confidence intervals. *Hazard ratios ad-
justed for cancer registry (to adjust for geography).
TABLE 2. Cox proportional hazards regression model for all-cause
and cancer-specific mortality for lobar versus sublobar resection
Variable
All-cause
mortality*
Cancer-specific
mortality*
Surgical approach
Sublobar Reference Reference
Lobectomy 0.56 (0.51–0.62) 0.53 (0.48–0.6)
Age (y)
<40 Reference Reference
40–49 0.84 (0.53–1.32) 0.82 (0.51–1.31)
50–59 0.92 (0.6–1.3) 0.8 (0.51–1.26)
60–69 1.11 (0.74–1.69) 0.93 (0.6–1.61)
70–79 1.38 (0.91–2.09) 1.04 (0.67–1.61)
>80 1.92 (1.26–2.94) 1.27 (0.81–2)
Race
White Reference Reference
Black 1.22 (1.07–1.41) 1.28 (1.1–1.5)
Other 1.05 (0.91–1.21) 1.1 (0.93–1.3)
Gender
Female Reference Reference
Male 1.53 (1.42–1.65) 1.43 (1.31–1.56)
Tumor size (cm)
<2 Reference Reference
2–2.9 1.01 (0.91–1.11) 0.95 (0.84–1.07)
3–3.9 1.28 (1.15–1.43) 1.26 (1.11–1.44)
4–4.9 1.94 (1.69–2.23) 2.08 (1.77–2.44)
5–5.9 1.83 (1.54–2.18) 2.0 (1.64–2.44)
6–6.9 2.53 (2.04–3.12) 2.93 (2.32–3.7)
7 3.6 (3.13–4.14) 4.37 (3.74–5.09)
Lymph nodes examined (n)
0 Reference Reference
1–10 0.83 (0.76–0.9) 0.81 (0.74–0.89)
11–16 0.7 (0.61–0.81) 0.69 (0.58–0.81)
17 0.65 (0.54–0.8) 0.67 (0.54–0.84)
Grade
Well differentiated Reference Reference
Moderately differentiated 1.4 (1.27–1.54) 1.39 (1.23–1.56)
Poorly differentiated 2.13 (1.88–2.42) 2.51 (2.17–2.9)
Undifferentiated 1.34 (1.22–1.48) 1.38 (1.23–1.55)
Data presented as hazard ratio, with 95% confidence intervals in parentheses. *Haz-
ard ratios adjusted for cancer registry (to adjust for geography).
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set revealed that BAC is associated with superior survival
rates compared with other histologic types.24 Data from
single-institution studies have supported this finding. Cam-
pione and colleagues25 evaluated 224 patients with Stage IA
NSCLC, of whom 54 had BAC. These 54 patients with BAC
were found to have significantly (P ¼ .04) superior 5-year
survival (88%) compared with all other histologic types
(54%). On multivariate analysis, they found that non–
BAC NSCLC histologic features were independently asso-
ciated with a sevenfold increased risk of death.
The traditional approach to BAC surgical treatment has,
to some degree, revolved around the radiographic appear-
ance.13,21,26,27 Infiltrative lesions, based on the radiographic
appearance, have correlated with mucinous histologicThe Journal of Thoracic and Cafeatures.Mass-like lesions have correlatedwith nonmucinous
histologic features.13 Some investigators have attempted to
ascertain methods to identify in situ lesions. Ohori and Santa
Maria28 evaluated broncheoalveolar lavage cytology speci-
mensandhistologic features.They found that althoughacom-
ponent of in situ histologic features was present, the final
determinationwould involve a correlationwith a combination
of clinical, radiographic, and histologic data.28
In recent years, the interest in limited anatomic resections
(ie, segmentectomies) has increased.4-7 This is, to some
degree, driven by a desire to limit the extent of
parenchymal resection1-3 and preserve as much functionalrdiovascular Surgery c Volume 143, Number 3 595
TABLE 4. Cox proportional hazards regression model for all-cause
and cancer-specific mortality for lobar versus segmentectomy versus
wedge resections grouped by tumor diameter (size)
Surgical approach
All-cause
mortality*
Cancer-specific
mortality*
Tumor 2 cm
Wedge Reference Reference
Segmentectomy 0.44 (0.27–0.71) 0.34 (0.18–0.62)
Lobectomy 0.53 (0.48–0.63) 0.47 (0.38–0.57)
Tumor>2 cm
Wedge Reference Reference
Segmentectomy 0.7 (0.45–1.08) 0.67 (0.4–1.12)
Lobectomy 0.64 (0.52–0.77) 0.64 (0.51–0.81)
Data presented as hazard ratio, with 95% confidence intervals in parentheses. *Haz-
ard ratios adjusted for cancer registry (to adjust for geography), age in decades, race,
gender, grade of tumor, and lymph node number.
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rates in patients with BAC, the benefit of lobectomy for
these patients is uncertain. The role of a nonanatomic
resection for the treatment of BAC has been
advocated.15,16,29,30 Previous studies that examined the
effect of the extent of resection on survival in patients
with BAC have been limited to single-institutional
series.17-19
Consequently, we used a large population data set to ex-
amine the effect of the extent of resection on survival in pa-
tients with BAC. We found that patients who underwent
anatomic resection (ie, segmentectomy or lobectomy) had
superior survival rates compared with those undergoing
nonanatomic resection (ie, wedge resection). Its pattern of
spread might explain our finding of improved survival
with anatomic resection.
By definition, tumors that are pure BAC infiltrate along
the bronchial and alveolar structure and should not metasta-
size to the lymph nodes. However, what we have found in
our data was that there does appear to be a role for lymph
node evaluation in the treatment of these patients. These
data are likely a surrogate for the inaccuracy in the patho-
logic evaluation of the tumors. These tumors might have
had other histologic subtypes involved. Alternatively, they
were coded as BAC because their histologic findings had
BAC features.
Histologically, BAC arises from terminal bronchiolar and
acinar epithelial tissue. It has a ‘‘lepidic’’ pattern of growth
(growth along pre-existing alveolar structures). To some de-
gree, this limits its invasiveness, as demonstrated by a lack
of stromal, vascular, or pleural invasion.21 As a consequence
of this pattern of spread, anatomic resection might provide
improved outcomes by removing residual areas or tumor
nests or removing the draining lymphatics.
Its degree of differentiation and its typical pattern of
spread might explain improve outcomes with BAC. The
BAC grade typically found on pathologic examination is
well differentiated or moderately differentiated.21 In our596 The Journal of Thoracic and Cardiovascular Surgstudy, we also found this to be true. Well-differentiated
and moderately differentiated grades of tumors were the
greatest proportion of tumors.
BAC lesions have a tendency to be nodular or a consolida-
tive/lobar process.21 Dumont and colleagues26 evaluated 97
patients with BAC and found that 85% presented as nodules
and 15% as a pneumonitis or diffusely infiltrative process.
Mucinous histologic features comprised 43% of specimens,
and 12% were multicentric or diffuse.26 Invasive patterns
are predictive of survival.27 The pathologic findings corre-
late with the computed tomography (CT) findings.
Sawada and colleagues31 found that BAC tends to have
a solid or partly solid attenuation pattern with air-
containing spaces and a lack of contractive features. BAC
tumors also demonstrate a low maximum standardized up-
take value on fluordeoxyglucose positron emission tomog-
raphy (PET).31 Bryant and Cerfolio32 found that the
maximal standardized uptake value of CT/PET had diffi-
culty in predicting the malignant nature of BAC histologic
features. In their study of 585 patients with pulmonary nod-
ules, of which 496 ultimately were found to be malignant,
23 had BAC histologic features. A total of 17 false-
negative results were found with CT/PET imaging. BAC
constituted 11, or 65% (11 of 17), of all the false-
negative findings and 48% (11 of 23) of all the patients
with BAC.
With this degree of intraparenchymal spread and the
inability to localize or predict BAC pathology clinically
with CT/PET, we sought to determine whether the
variations in the extent of resection for BAC histologic
features were appropriate in terms of their influence
on survival.
Through multivariate analysis, we found that lobar resec-
tion did yield superior overall all-cause and cancer-specific
mortality compared with sublobar resection. Additionally,
we found that when an anatomic resection was performed,
compared with a nonanatomic wedge resection, similar su-
perior overall all-cause and cancer-specific mortality was
obtained. This makes intuitive sense when one reflects on
the histologic nature of BAC and its lepidic growth pattern
described.
With our Cox proportional hazard models, we uniformly
found that an increasing tumor size correlated with an in-
crease in the hazard ratio for mortality. Not surprisingly,
this has been echoed in the published NSCLC data.25 In ad-
dition, this has been found in the BAC-specific data. Cam-
pione and colleagues25 found that those with tumors less
than 2 cm in diameter had improved survival (P ¼ .0109).
Similarly, in a study by Oka and colleagues33 in which
the mucinous BAC subset of NSCLC was studied, they
found that lesions less than 3 cm had 5-year survival of
100% and those with tumor greater than 3 cm had survival
of only 25.1%. Although the Pittsburgh group has sug-
gested that lesions less than 2 cm might be amenable toery c March 2012
Whitson et al General Thoracic Surgery
G
T
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that for segmentectomy to be performed for BAC, the lesion
should be less than 2 cm in diameter and the margin greater
than 2 cm. These criteria are in evolution.
BAC has been associated with the young, those with lim-
ited or no smoking history, and those of Asian descent.12We
found that women constituted a greater proportion of the
cases than did men and that most patients were self-
described as white. An explanation for why the distribution
of race in our study was predominantly white could be a re-
flection of the distribution of white and Asian people found
in the United States. In our multivariate analysis, women
did fare significantly better than men. Blacks had a greater
hazard ratio of mortality. Age did not appear to be associ-
ated with an increased risk, except for those older than 80
years, in the all-cause mortality analysis.
The implications of these data presented in the present re-
port will undoubtedly be an interpretation in process as the
International Association for the Study of Lung Cancer re-
defined BAC in early 2011.14 In that publication, Travis and
colleagues14 stated that the terms ‘‘BAC’’ and ‘‘mixed sub-
type adenocarcinoma’’ should be removed from use. Le-
sions with pure lepidic growth should be classified as
adenocarcinoma in situ and those with a predominant lepi-
dic growth and less than 5 mm of invasion should be defined
as minimally invasive adenocarcinoma. The term ‘‘invasive
adenocarcinoma’’ is added with multiple variants. Mucin-
ous BAC is reclassified as invasive mucinous adenocarci-
noma.14 Although the nomenclature has changed, the
concepts for the separate histologic types remain.
The spectrum of lung adenocarcinoma might not be
a continuum. Yatabe and colleagues34 have commented
that the distribution might be more the results of different
molecular pathway involvement. This perspective might
be the most accurate.
With the recent International Association for the Study of
Lung Cancer nomenclature change, several investigators
have re-evaluated the long-term outcomes of NSCLC resec-
tion with the new classification. What they found is that the
degree of invasiveness might be more of a prognosticator
than previously thought. In their re-evaluation of 514 pa-
tients with Stage I adenocarcinoma, Yoshizawa and col-
leagues35 found 3 degrees of invasiveness: low,
intermediate, and high. Of those patients with a ‘‘low’’ clas-
sification (adenocarcinoma in situ and minimally invasive
adenocarcinoma), the 5-year survival was 100%. In the
‘‘intermediate’’ group (nonmucinous lepidic predominant,
papillary predominant, and acinar predominant), the
5-year survival was 83% to 90%. For the ‘‘high’’ group (in-
vasive mucinous adenocarcinoma, colloid predominant,
solid predominant, and micropapillary), the 5-year survival
was 67% to 71%.35 Russell and colleagues36 re-evaluated
210 patients. Those who were found to have adenocarci-
noma in situ, minimally invasive adenocarcinoma, orThe Journal of Thoracic and Calepidic predominant adenocarcinoma histologic types had
near 100% 5-year survival.36
The Kaplan-Meier survival curves that our data have gen-
erated could represent 3 possible scenarios. The first is that
these are the true survival of patients with BAC who were
surgically treated. They might also represent those of pa-
tients with mixed cell histologic types. There might be
more aggressive histologic types included with the BAC
cell type. If these more aggressive tumors were under-
recognized, the tumor size, degree of lymphadenectomy,
and extent of the resection would undoubtedly play
a more important role. If an intermediate grade is present,
a slow steady decline could be interpreted. The latter 2 pos-
sibilities could be representative in the curves in the early or
late portions, respectively.
In patients with mixed histologic features, treatment
should be based on the non-BAC histologic type. The
size, degree of lymph node involvement, pulmonary func-
tion, and anatomic location should all be taken into account
in the decision to performwedge resection, segmentectomy,
or lobectomy in their treatment. With time, what might be
seen is an effect similar to that reported by Zell and col-
leagues37 after the 1999 World Health Organization reclas-
sification in which survival improved, and this might have
resulted from the more accurate classification.
Strengths and Limitations
We used retrospective data and, as such, our study had the
inherent limitations of all observational studies, particularly
selectionbias.Amyriadof clinical data are consideredduring
the operative selection of patients; however, we were unable
to account for all these factors. No coded variables or data on
patient fitness or pulmonary function are available, either at
resection or after. Also, the data are coded by the local data
registrar. The guidelines for data registry are provided by
the National Cancer Institute’s SEER. The data set spans 3
decades, and the pathologic evaluation and classification
has changed (most recently at theWorldHealthOrganization
consensus conference in November 2004 with the Interna-
tional Association for the Study of Lung Cancer and Ameri-
can Society of Clinical Oncology). Data on the 2011 BAC
nomenclature changes14 were not reflected in the data set.
The data coded in the SEER database are that of the dom-
inant histologic findings. The argument that might have
been miscoded and as such the outcomes might not have
been driven by the BAC component but by the mixed histo-
logic features not reported is conceded. Institutional varia-
tions in pathologic reporting describing adenocarcinoma
with BAC features might have affected the classification
in SEER. Future submissions to the SEER database should
be adjusted to the new International Association for the
Study of Lung Cancer coding changes of adenocarcinoma
in situ, minimally invasive adenocarcinoma, and invasive
adenocarcinoma.rdiovascular Surgery c Volume 143, Number 3 597
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the SEER database. In particular, we could not assess the
surgical approach (ie, thoracotomy vs thoracoscopy), sur-
geon or hospital volume, tumor recurrence, pretreatment
staging, or use of chemotherapy. Data on whether mediasti-
nal lymph node evaluation was used or the method under-
taken were not available.
Despite these limitations, our study had a number of
strengths. We had a large cohort, with more than 6800 pa-
tients included in our study. Although our study was neither
prospective nor randomized, it was multi-institutional. Be-
cause our study used population-based data, it reflects the
practice and patterns of care across the United States and
is an accurate reflection of the outcomes and treatment of
the population of patients treated.
CONCLUSIONS
Using the National Cancer Institute population-based
SEER data set, we have found that in patients with BAC his-
tologic features, undergoing lobar or anatomic resection
does confer a significant survival advantage compared
with sublobar or nonanatomic resection. Increasing tumor
size portends an increased mortality risk. More extensive
lymphadenectomy also appears to be beneficial. This find-
ing might result from mixed tumor histologic features.
More de-differentiated tumors have worse prognoses than
do well-differentiated tumors. A move to the new nomen-
clature14 should be adopted. The terms adenocarcinoma in
situ, minimally invasive adenocarcinoma, and the predom-
inant cell type should be the standard and replace the term
‘‘bronchoalveolar carcinoma.’’ These findings have poten-
tially important implications for thoracic surgeons and war-
rant additional detailed investigation.
References
1. Lucchi M, Melfi F, Ribechini A, Dini P, Duranti L, Fontanini G, et al. Sleeve and
wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the
bronchial airway. J Thorac Cardiovasc Surg. 2007;134:373-7.
2. Rendina EA, Venuta F, de Giacomo T, Rossi M, Coloni GF. Parenchymal sparing
operations for bronchogenic carcinoma. Surg Clin North Am. 2002;82:589-609,
vii.
3. Yavuzer S, Yuksel C, Kutlay H. Segmental bronchial sleeve resection: preserving
all lung parenchyma for benign/low-grade neoplasms. Ann Thorac Surg. 2010;
89:1737-43.
4. Okumura M, Goto M, Ideguchi K, Tamura M, Sasaki H, Tanaka H, et al. Factors
associated with outcome of segmentectomy for non-small cell lung cancer: long-
term follow-up study at a single institution in Japan. Lung Cancer. 2007;58:
231-7.
5. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N.
Effect of tumor size on prognosis in patients with non-small cell lung cancer:
the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc
Surg. 2005;129:87-93.
6. Shapiro M, Weiser TS, Wisnivesky JP, Chin C, Arustamyan M, Swanson SJ.
Thoracoscopic segmentectomy compares favorably with thoracoscopic lobec-
tomy for patients with small stage I lung cancer. J Thorac Cardiovasc Surg.
2009;137:1388-93.
7. Schuchert MJ, Pettiford BL, Keeley S, D’Amato TA, Kilic A, Close J, et al.
Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer.
Ann Thorac Surg. 2007;84:926-33.598 The Journal of Thoracic and Cardiovascular Surg8. Ginsberg RJ, Rubinstein LV; Lung Cancer Study Group. Randomized trial of lo-
bectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann
Thorac Surg. 1995;60:615-23.
9. Whitson BA, Groth SS, Andrade RS, Maddaus MA, Habermann EB, D’Cunha J.
Survival after lobectomy vs. segmentectomy for stage I non-small cell lung can-
cer: a population-based analysis. Ann Thorac Surg. 2011;92:1943-50.
10. TravisWD, Garg K, FranklinWA,Wistuba II, Sabloff B, Noguchi M, et al. Bron-
chioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and
research relevance of the 2004 World Health Organization pathologic criteria.
J Thorac Oncol. 2006;1:S13-9.
11. Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML. Systemic approaches
for multifocal bronchioloalveolar carcinoma: is there an appropriate target? On-
cology (Williston Park). 2010;24:888-98, 900.
12. Garfield DH, Cadranel JL,WislezM, FranklinWA, Hirsch FR. The bronchioloal-
veolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac
Oncol. 2006;1:344-59.
13. Okubo K, Mark EJ, Flieder D, Wain JC, Wright CD, Moncure AC, et al. Bron-
choalveolar carcinoma: clinical, radiologic, and pathologic factors and survival.
J Thorac Cardiovasc Surg. 1999;118:702-9.
14. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y,
et al. International association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society International multidisciplinary classifica-
tion of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-85.
15. Bilfinger TV, BaramD. Sublobar resection in nonsmall cell lung carcinoma. Curr
Opin Pulm Med. 2008;14:292-6.
16. Rusch VW, Tsuchiya R, Tsuboi M, Pass HI, Grunenwald D, Goldstraw P. Surgery
for bronchioloalveolar carcinoma and ‘‘very early’’ adenocarcinoma: an evolv-
ing standard of care? J Thorac Oncol. 2006;1:S27-31.
17. Yamato Y, Tsuchida M, Watanabe T, Aoki T, Koizumi N, Umezu H, et al. Early
results of a prospective study of limited resection for bronchioloalveolar adeno-
carcinoma of the lung. Ann Thorac Surg. 2001;71:971-4.
18. Watanabe S, Watanabe T, Arai K, Kasai T, Haratake J, Urayama H. Results of
wedge resection for focal bronchioloalveolar carcinoma showing pure ground-
glass attenuation on computed tomography. Ann Thorac Surg. 2002;73:1071-5.
19. Sakurai H, Dobashi Y,Mizutani E,Matsubara H, Suzuki S, Takano K, et al. Bron-
chioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognos-
tic assessment. Ann Thorac Surg. 2004;78:1728-33.
20. Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and
the number of lymph nodes sampled during resection of node-negative non-small
cell lung cancer. Chest. 2005;128:1545-50.
21. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health
Organization, International Agency for Research on Cancer, International Asso-
ciation for the Study of Lung Cancer, International Academy of Pathology, Pa-
thology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart.
Oxford, England: IARC Press, Oxford University Press; 2004:10-25, 35-44.
22. Raz DJ, Kim JY, Jablons DM. Diagnosis and treatment of bronchioloalveolar car-
cinoma. Curr Opin Pulm Med. 2007;13:290-6.
23. McVay CL, Pickens A, Fuller C, Houck W, McKenna R Jr. VATS anatomic pul-
monary resection in octogenarians. Am Surg. 2005;71:791-3.
24. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology
of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER
database. Lung Cancer. 2004;45:137-42.
25. Campione A, Ligabue T, Luzzi L, Ghiribelli C, Paladini P, Voltolini L, et al.
Impact of size, histology, and gender on stage IA non-small cell lung cancer.
Asian Cardiovasc Thorac Ann. 2004;12:149-53.
26. Dumont P, Gasser B, Rouge C, Massard G, Wihlm JM. Bronchoalveolar carci-
noma: histopathologic study of evolution in a series of 105 surgically treated pa-
tients. Chest. 1998;113:391-5.
27. Schmidt L, Myers J. Bronchioloalveolar carcinoma and the significance of inva-
sion: predicting biologic behavior. Arch Pathol Lab Med. 2010;134:1450-4.
28. Ohori NP, Santa Maria EL. Cytopathologic diagnosis of bronchioloalveolar car-
cinoma: does it correlate with the 1999 World Health Organization definition?
Am J Clin Pathol. 2004;122:44-50.
29. Yoshioka M, Ichiguchi O. Selection of sublobar resection for c-stage IA non-
small cell lung cancer based on a combination of structural imaging by CT and
functional imaging by FDG PET. Ann Thorac Cardiovasc Surg. 2009;15:82-8.
30. Yoshida J. Management of the peripheral small ground-glass opacities. Thorac
Surg Clin. 2007;17:191-201, viii.
31. Sawada E, Nambu A, Motosugi U, et al. Localized mucinous bronchioloalveolar
carcinoma of the lung: thin-section computed tomography and fluorodeoxyglu-
cose positron emission tomography findings. Jpn J Radiol. 2010;28:251-8.ery c March 2012
Whitson et al General Thoracic Surgery32. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated
FDG-PET/CT is useful in differentiating benign from malignant pulmonary
nodules. Ann Thorac Surg. 2006;82:1016-20.
33. Oka S, Hanagiri T, Uramoto H, et al. Surgical resection for patients with mucin-
ous bronchioloalveolar carcinoma. Asian J Surg. 2010;33:89-93.
34. Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a step-
wise progression? Lung Cancer. 2011;74:7-11.
35. Yoshizawa A,Motoi N, Riely GJ, Sima CS, GeraldWL, Kris MG, et al. Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic
subgroups and implications for further revision of staging based on analysis of
514 stage I cases. Mod Pathol. 2011;24:653-64.
36. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does
lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study
based on the new International Association for the Study of Lung Cancer/Amer-
ican Thoracic Society/European Respiratory Society international multidisci-
plinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6:1496-504.
37. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar
carcinoma: improvement in survival after release of the 1999WHO classification
of lung tumors. J Clin Oncol. 2005;23:8396-405.G
T
SDiscussion
Dr Ross Bremner (Phoenix, Ariz). Thanks very much, Bryan.
What a great presentation, and thank you for a well-written report.
Your study has attempted to clarify a surgical approach to bron-
choalveolar cell carcinoma (BAC) using this large cohort of pa-
tients from the Surveillance, Epidemiology, and End Results
(SEER) database and from a long time period, from 1998 to
2007. It does suffer from the limitations of the SEER database,
which have already been discussed at this meeting, but I laud
your attempt to try to provide some clarification on how we should
approach these patients.
The term ‘‘BAC’’ was originally coined to describe this lipidic
growth pattern of a well-differentiated noninvasive cancer, and
a paradigm was developed that because these lesions are noninva-
sive and well behaved that we should perform a parenchymal-spar-
ing operation and that wedge resection is actually acceptable.
I would say that probably this is how we mostly approach these le-
sions throughout the United States. This report challenges that and
concludes that a more formal resection, such as lobectomy or for-
mal segmentectomy, is necessary. However, our understanding and
classification of this so-called BAC has changed a lot since 1988,
making interpretation of these data quite difficult. I am quite sure
that your data include some patients that we would now say have
a diagnosis of invasive carcinoma in a background of BAC, which
is really a different disease. Thus, my first question is, can you clar-
ify what you think the pathology is in these patients? As you know,
we now have a more recent classification of adenocarcinoma in
situ, minimally invasive adenocarcinoma, and lipidic-predominant
adenocarcinoma, all of which actually have about 100% 5-year
survival if we resect the tumor. What do you think the pathology
is in this retrospective database? Also, do you think that there is
any way we can try to clarify the pathology? Is there any mecha-
nism where we could go back historically to do that?
Dr Whitson. Yes, answers to some of those questions we can
attempt to obtain from the datawe have available. Somewe cannot.
From what is coded in the SEER registry, you are very correct—it
covers essentially 2 decades worth of data. The predominant cell
type is what is recorded by the registrars and we are unfortunately
left to the registrar’s discretion or the pathologist who interprets
those slides as to what that is and how it is reported. For our eval-
uation, we selected those that were coded as bronchoalveolar as theThe Journal of Thoracic and Capredominant cell type. Those that were mostly adenocarcinoma,
we excluded. However, given the size and span of the registries
over the entire United States, there is sure to be some overlap, de-
pending on who interpreted those slides.
What we could do to try to answer your question about looking
at some of the more recent histologic classifications that came out
through International Association for the Study of Lung Cancer in
the spring, although we cannot go back to these data and say what
is a lepidic growth pattern versus those that are not, we could look
at mucinous histologic findings and those that are nonmucinous
and that might be a way to interpret the invasive mucinous adeno-
carcinomas. That is the extent of the data that we have from the
SEER database.
Dr Bremner. I would submit to you that there is a danger in this
report that the difference that we see between these groups of pa-
tients is that they have included invasive carcinoma, which we
would not include in our current diagnosis of—a term that I think
needs to be dropped, which I think is BAC—a term that we will
soon not be using anymore.
Dr Whitson. I think as we go forward, that term—bronchoal-
veolar carcinoma—is going to go away and you have adenocarci-
noma in situ, invasive mucinous adenocarcinoma, and such. How
these get coded in the SEER database and how we look at things
from an institutional perspective in comparing previous data to
data going forward is going to have to be looked at quite carefully.
Dr Bremner. I imagine that pulmonary function played a role in
the surgeon’s decision to do either wedge or lobectomy. Do you
have any data on the pulmonary function test findings in these
patients?
DrWhitson.No. Unfortunately, no data on pulmonary function
test findings or fitness in the SEER data.
Dr Bremner. Just to reiterate, I worry that we are going to send
a message that patients who have BAC now need to undergo lobec-
tomy when, our current histology and understanding, is that BAC
is really going to be a noninvasive lesion and should be approached
with parenchymal-sparing surgery.
Thanks very much and I am sure this was a fantastic exercise in
lots of statistics.
Dr Whitson. Thank you very much. I would take Dr Bremner
a different perspective. I would not necessarily say that they all
need to undergo lobectomy, but we need to look at that data in con-
cert with some of the data coming from the Cancer and Leukemia
Group B trial about the tumor size. If one had a small lesion, per-
haps wedge resection is adequate—I don’t know, segmentec-
tomy—probably for sure for those less than 2-cm lesions. The
decision would be determined by the cell type and whether it
were a pure histologic type or not. Lymphadenectomies are not be-
ing performed. That might be as much or as more important as per-
forming the anatomic resection just as a surrogate. In theory,
lymph nodes are not important in BAC, but as we have shown
from these data, they do appear to be involved in some fashion.
Dr DouglasWood (Seattle, Wash). I am going to pick up where
Ross left off and also be critical—I am sorry—because I think that
this report, despite being technically very well done, is providing
a dangerous and regressive message that is actually erroneous for
exactly the reasons that Ross just interpreted. Unfortunately, the
SEER database, with which I am very familiar, has no ability to
discriminate between our current definitions of noninvasiverdiovascular Surgery c Volume 143, Number 3 599
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cinoma with bronchoalveolar features, which is just invasive ade-
nocarcinoma. By definition, pure bronchoalveolar carcinoma is
a noninvasive tumor and therefore it does not have the ability to
develop lymphatic invasion that would involve the lymph nodes;
thus, your whole premise of the extent of lymph node dissection
is not justified and neither is your argument about the extent of pa-
renchymal resection. By definition, a noninvasive cancer does not
have access to the lymphatics and it is not able to spread to the
lymph nodes. Now, you are right that there might be a component
of invasive carcinoma within that apparent bronchoalveolar carci-
noma so there could be the occasional error; however, by our
current better definitions of pathologic analysis of pure bronchoal-
veolar carcinoma or noninvasive tumor, the extent of lymph node
involvement or dissection should not matter. So, I am worried
about the wrong message being delivered when we have become
better at defining a patient population that does not require lobec-
tomy. Others will misinterpret your findings that obviously include
a wide spectrum of invasive carcinoma as potentially pushing us
back toward more aggressive resection for pure bronchoalveolar
carcinoma or noninvasive adenocarcinoma.
Dr Whitson. That is a very good point, and we do need to look
critically at that.
Dr Scott Swanson (Boston, Mass). I liked the report. One ques-
tion about your survival analysis in terms of anatomic or nonana-
tomic. Is that independent of lymph nodes or is that associated with
the nodal removal?
Dr Whitson. Those 4 categories of lymph node evaluation—
you mean for the Kaplan-Meier curve?
Dr Swanson. Yes, when you showed survival by lobectomy
segmentectomy versus wedge. Is that independent of nodal sam-
pling? Is that univariate or multivariate?
Dr Whitson. That was a multivariate analysis, but it was with
the lymph nodes not evaluated as a continuous variable but as those
4 subcategories of 0, 1 to 10, 11 to 16, or greater than 17.
Dr Swanson. So an anatomic resection independent of nodal re-
moval is a better option.600 The Journal of Thoracic and Cardiovascular SurgDr Whitson. Better than a wedge, yes, sir, but given the histo-
logic conversation we just had.
Dr Joseph Shrager (Stanford, Calif). So, the point has been
made several times, I think correctly, that the report does not really
say anything about what used to be called pure bronchioloalveolar
carcinoma. But, it does say something very strong, I think, about
smaller invasive carcinomas or probably what most of us are see-
ing a lot of—which are these tumors that are sort of half ground-
glass and half invasive. The very strong statement that this report
is saying about those tumors is that segmentectomy seems a lot
better than wedge in that situation. Now, we do not know from
your data, the fine points. You know, the Japanese say over and
over that 50% is the cutoff point, that if it is less than 50% invasive,
you can basically do a wedge, and if it is greater than 50% solid on
computed tomography, you cannot. You do not have that degree of
fine hair-splitting here, but I think it is important to make that
point—that segmentectomy is looking a lot better than wedge.
Dr Whitson. We tend to agree with you, Dr Shrager.
Dr Paul Schipper (Portland, Ore). Just a quick comment on
what Doug said. I had the opportunity to read your report, and I
think the methodology is very good, but that one input that you
had, that kind of muddy definition of BACmakes the results some-
thing, maybe, that we cannot use. However, now we have this new
definition of adenocarcinoma in situ and at some point, 5 years
down the road, you are going to be able to take that one and
plug it into this method.We do not have the opportunity of defining
what tumors are going to do. They do what they do, and we sort of
see what happens. I guess I would say that this study would need to
be repeated with that carcinoma in situ population. Just to perhaps
make an analogy, we operate on high-grade dysplasia, and that also
is an in situ lesion, but we know a certain percentage of the time, it
is not. I think it would be worth repeating this in a number of years
looking at carcinoma in situ and not just depending on your pathol-
ogist saying this tumor does not look to be invasive and therefore it
is not going to be in the lymph nodes. We need to see whether that
is in fact the truth.
Dr Whitson. Very good point. Thank you, sir.ery c March 2012
TABLE E1. Lobectomy versus sublobar cohort demographics
Variable Lobectomy Sublobar P value
Patients (n) 5532 1278
Age (y) .0005
<40 0.7 1.3
40–49 5.0 4.4
50–59 16.3 13.4
60–69 32.3 29.7
70–79 35.7 39.2
>80 10.0 12.0
Race .0029
White 83.7 83.6
Black 6.6 8.8
Other 9.7 7.6
Gender .56
Male 37.7 36.9
Female 62.3 63.2
Tumor size (cm) <.0001
<2 24.9 47.7
2–2.9 32.1 29.7
3–3.9 19.6 12.4
4–4.9 8.9 4
5–5.9 4.6 2.6
6–6.9 3.0 1
7 7 3.6
Lymph nodes examined <.0001
0 8.4 61.9
1–10 70.6 33.3
11–16 13.6 3.4
17 7.5 1.4
Histologic type .11
Not otherwise specified 88.2 86.1
Alveolar carcinoma 1.0 1.0
Nonmucinous 4.4 6
Mucinous 5.5 6.3
Mixed type 0.9 0.6
Grade .041
Well differentiated 45.6 48.3
Moderately differentiated 42.2 37.8
Poorly differentiated 11.5 12.7
Undifferentiated 0.6 1.2
Data presented as percentages.
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